Ronald King

A new report shows home price growth in Opportunity Zones is trailing the broader market, raising questions about the program's impact ahead of a major overhaul.

As A-ROSA marks 25 years, its new 'Cruise Your Way' strategy is more than a slogan. It’s a systemic overhaul powered by guest choice and sustainable tech.

Generative AI created an ocean of ad content. Now, a new system aims to find the drops that matter by decoding emotion and automating creative decisions.

ZincFive's SPAC merger isn't just a deal; it's a bet on the critical battery chemistry needed to sustain the world's insatiable AI power demands.

With vast mineral wealth and high ESG standards, Canada is the EU's ideal partner to break free from risky supply chains. But can it turn potential into pipelines?

A German workwear brand's sponsorship of a US baseball game on Netflix isn't just an ad. It's a look at the new rules of global media, industry, and labor.

A startup is offering a $2,500 campus safety toolkit to universities for free. Is it a lifeline for strained budgets or a calculated move to rewire the industry?

A landmark deal between software firm MHC and industrial giant BlueCrest isn't just about technology; it's a structural shift merging AI with mail infrastructure.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

A virtual cardiology practice is one of America's fastest-growing firms. It's not just a business success; it's a structural shift in healthcare.

A five-year growth streak for one tech firm signals a massive structural shift. Nonprofits are adopting the tools of modern industry to build a new engine for generosity.

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

A team led by Stratom is developing an autonomous logistics system to support troops in contested zones, reducing risk and reshaping military sustainment.

New high-grade copper results from Blue Moon's Nussir project aren't just a win for the company. They're a critical step in building Europe's resource independence.

In Miami's booming luxury market, access is everything. Uncover the developer-broker system that dictates who buys the best condos, and when.

A new pet food brand just won a major award. It reflects a systemic change in the $158B pet care economy, rewriting the rules of global competition.

A new line of matcha products reveals more than just new flavors; it's a blueprint for how consumer goods giants are winning the battle for the kitchen counter.

Thinkific's Q2 results reveal a company in deep transition, balancing heavy AI investment and a strategic upmarket push against the immediate need for profit.

AI is no longer just a chatbot. Autonomous agents are now handling real work, creating massive security gaps. A new partnership aims to make them visible.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.